Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30352488 | 1.00 | PYCR1 (0.47) | PYCR1PTGDR2SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL14525317 | 0.84 | S1PR1 (0.41) | PYCR1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15978831 | 0.83 | ESR1 (0.42) | PYCR1PTGDR2MAPTMEN1KMT2A | |
| SCHEMBL5820 | 0.83 | PYCR1 (0.45) | PYCR1ALDH1A1MAPTNPSR1HPGD | |
| SCHEMBL606473 | 0.82 | PTGDR2 (0.44) | PYCR1PTGDR2SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL20378745 | 0.79 | PYCR1 (0.42) | PYCR1SLC6A2SLC6A4ALDH1A1MAPT | |
| SCHEMBL307129 | 0.79 | PYCR1 (0.49) | PYCR1ALDH1A1MAPTNPSR1SIGMAR1 | |
| SCHEMBL30169578 | 0.79 | PYCR1 (0.49) | PYCR1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL12164465 | 0.79 | PYCR1 (0.49) | PYCR1ALDH1A1MAPTLMNANPSR1 | |
| SCHEMBL29676673 | 0.79 | PYCR1 (0.49) | PYCR1ALDH1A1MAPTNPSR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| CN-118804915-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118344338-A | Substituted 4-aminoisoindoline-1, 3-dione compounds and their use for the treatment of lymphomas | 细胞基因公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | disclosed |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-06-25 | — | — | US | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| EP-0594019-B1 | 1-Biphenylmethyl-pyridone derivatives, their preparation and their use as angiotensin II antagonistes | BAYER AG (DE) | 2000-02-23 | — | — | EP | disclosed |
| US-5863930-A | ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | disclosed |
| WO-1998057954-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| US-5596006-A | ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-01-21 | — | — | US | disclosed |
| EP-0328643-B1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO CORP (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0594019-A1 | Trisubstituted biphenyl as angiotensin II antagonistes | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
| US-5043142-A | Measuring peroxide-active substances | TERUMO KABUSHIKI KAISHA (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0328643-A1 | (alpha)-HYDROPEROXYISOPROPYLPHENYL COMPOUNDS AND PROCESS FOR THEIR PREPARATION | TERUMO KABUSHIKI KAISHA (JP) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | PYCR1 1671/4885PTGDR2 689/4885SLC6A2 3715/4885 |
| US-12016852-B2 | Pyrrolidine glycosidase inhibitors | PREP, GAA, DNPEP | PYCR1 1317/4885PTGDR2 3803/4885SLC6A2 1212/4885 |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AANAT, HTR2C, AADAT | PYCR1 533/4885PTGDR2 625/4885SLC6A2 368/4885 |
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | PYCR1 2261/4885PTGDR2 154/4885SLC6A2 65/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | PYCR1 3964/4885PTGDR2 4202/4885SLC6A2 4491/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | PYCR1 4526/4885PTGDR2 3784/4885SLC6A2 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.